Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug ...

Biogen 30-Day Option Volume & Interest Snapshot Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today ...

Stay informed and make strategic decisions with our Ratings Table. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.

Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) and Idec (classic blood cancer drug Rituxan). The firm expanded its neurology portfolio ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...

Rituximab (Rituxan/MabThera; Biogen Idec/Genentech/Roche), a chimeric anti-CD20 monoclonal antibody, was tipped to be the first therapy approved for SLE in decades, but it failed to meet the ...

This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody against α4 integrin, and most recently, the PEGylated humanized anti-TNF-α antibody fragment ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...